Early Response to Anti-VEGF Therapy for Macular Edema and Longterm Outcomes
Author Information
Author(s): Gunay Betul Onal, Erdogan Gurkan, Akalin Irfan, Kalkisim Ahmet, Esenulku Cenap Mahmut, Gunay Murat
Primary Institution: Trabzon Kanuni Training and Research Hospital, University of Health Sciences, Trabzon, Turkey
Hypothesis
Is there a relationship between the first-day results of anti-VEGF therapy for macular edema due to vascular diseases and longterm outcomes?
Conclusion
The longterm anatomical outcomes of macular edema secondary to retinal vein occlusion and diabetic retinopathy may be predicted by treatment response 1 day after antivascular endothelial growth factor injection.
Supporting Evidence
- All patients with macular edema-retinal vein occlusion were good responders at post-injection day 1.
- Patients with macular edema-diabetic retinopathy had a lower rate of good response compared to those with macular edema-retinal vein occlusion.
- A significant decrease in central macular thickness was observed after anti-VEGF therapy.
- 1 of 42 total good responders had a central macular thickness >350 µm at the last visit.
Takeaway
Doctors can tell how well a treatment for eye swelling will work by looking at the results just one day after the first shot.
Methodology
Patients received anti-VEGF injections, and their central macular thickness was measured at various time points to assess treatment response.
Potential Biases
The use of two different anti-VEGF agents might influence the study outcomes.
Limitations
The study was retrospective, included a small number of patients, and lacked a control group.
Participant Demographics
58 patients (30 female, 28 male) with a mean age of 62.3 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website